Omega-3-fatty acids: Do they prevent cardiovascular disease?
Best Pract Res Clin Endocrinol Metab
; 37(3): 101681, 2023 05.
Article
in En
| MEDLINE
| ID: mdl-35739003
ABSTRACT
Despite cardiovascular disease (CVD) reductions with high-intensity statins, there remains residual risk among patients with metabolic disorders. Alongside low-density lipoproteins (LDL-C), elevated triglycerides (TG) are associated with incident CVD events. Omega-3 fatty acids (n3-FAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower TG levels, but their ability to reduce CV risk has been highly inconsistent. Trials using icosapent ethyl (IPE), a purified EPA ethyl ester, produced reductions in CVD events and atherosclerotic plaque regression compared with mixed EPA/DHA formulations despite similar TG-reductions. The separate effects of EPA and DHA on tissue distribution, oxidative stress, inflammation, membrane structure and endothelial function may contribute to these discordant outcomes. Additional mechanistic trials will provide further insights into the role of n3-FAs in reducing CVD risk beyond TG lowering.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Hypertriglyceridemia
/
Fatty Acids, Omega-3
Limits:
Humans
Language:
En
Journal:
Best Pract Res Clin Endocrinol Metab
Journal subject:
ENDOCRINOLOGIA
/
METABOLISMO
Year:
2023
Document type:
Article